Emerging drugs for ovarian cancer

Domenica Lorusso, Antonella Pietragalla, Sara Mainenti, Alessia Di Legge, Giulia Amadio, Giovanni Scambia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Importance of the field: Ovarian cancer has the highest mortality of all female reproductive tract cancers, which reflects both the absence of proven ovarian cancer screening tests and the development of drug-resistant cancer cell. Apart from varying the dosages, schedules, mode of delivery and combinations of existing drugs, efforts must continue to identify signaling pathways in tumor cells sufficiently different from normal cells that can be a target for maximizing tumor kill and minimizing toxicity. Areas covered in this review: Some of the most important cellular pathways are analyzed and discussed and the most interesting clinical trials, both closed and ongoing, described. What the reader will gain: The reader will gain a panoramic vision of all the most active drugs in clinical investigations in ovarian cancer. The reader will also better understand what the unresolved problems of molecular research are and how complicated the process 'from the bench to the bedside' is. Take home message: It is only with a strong commitment, cooperation and collaboration from the international ovarian cancer community that significant improvement in patient outcomes can be attained beyond the marginal gains achieved so far.

Original languageEnglish
Pages (from-to)635-652
Number of pages18
JournalExpert Opinion on Emerging Drugs
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Ovarian Neoplasms
Pharmaceutical Preparations
Neoplasms
International Cooperation
Drug Combinations
Early Detection of Cancer
Appointments and Schedules
Clinical Trials
Mortality
Research

Keywords

  • biological agents
  • ovarian cancer
  • target therapy
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lorusso, D., Pietragalla, A., Mainenti, S., Di Legge, A., Amadio, G., & Scambia, G. (2010). Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs, 15(4), 635-652. https://doi.org/10.1517/14728214.2010.502888

Emerging drugs for ovarian cancer. / Lorusso, Domenica; Pietragalla, Antonella; Mainenti, Sara; Di Legge, Alessia; Amadio, Giulia; Scambia, Giovanni.

In: Expert Opinion on Emerging Drugs, Vol. 15, No. 4, 12.2010, p. 635-652.

Research output: Contribution to journalArticle

Lorusso, D, Pietragalla, A, Mainenti, S, Di Legge, A, Amadio, G & Scambia, G 2010, 'Emerging drugs for ovarian cancer', Expert Opinion on Emerging Drugs, vol. 15, no. 4, pp. 635-652. https://doi.org/10.1517/14728214.2010.502888
Lorusso D, Pietragalla A, Mainenti S, Di Legge A, Amadio G, Scambia G. Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs. 2010 Dec;15(4):635-652. https://doi.org/10.1517/14728214.2010.502888
Lorusso, Domenica ; Pietragalla, Antonella ; Mainenti, Sara ; Di Legge, Alessia ; Amadio, Giulia ; Scambia, Giovanni. / Emerging drugs for ovarian cancer. In: Expert Opinion on Emerging Drugs. 2010 ; Vol. 15, No. 4. pp. 635-652.
@article{cfebed767a254c5f8e1c7b93f4cbf440,
title = "Emerging drugs for ovarian cancer",
abstract = "Importance of the field: Ovarian cancer has the highest mortality of all female reproductive tract cancers, which reflects both the absence of proven ovarian cancer screening tests and the development of drug-resistant cancer cell. Apart from varying the dosages, schedules, mode of delivery and combinations of existing drugs, efforts must continue to identify signaling pathways in tumor cells sufficiently different from normal cells that can be a target for maximizing tumor kill and minimizing toxicity. Areas covered in this review: Some of the most important cellular pathways are analyzed and discussed and the most interesting clinical trials, both closed and ongoing, described. What the reader will gain: The reader will gain a panoramic vision of all the most active drugs in clinical investigations in ovarian cancer. The reader will also better understand what the unresolved problems of molecular research are and how complicated the process 'from the bench to the bedside' is. Take home message: It is only with a strong commitment, cooperation and collaboration from the international ovarian cancer community that significant improvement in patient outcomes can be attained beyond the marginal gains achieved so far.",
keywords = "biological agents, ovarian cancer, target therapy, treatment",
author = "Domenica Lorusso and Antonella Pietragalla and Sara Mainenti and {Di Legge}, Alessia and Giulia Amadio and Giovanni Scambia",
year = "2010",
month = "12",
doi = "10.1517/14728214.2010.502888",
language = "English",
volume = "15",
pages = "635--652",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging drugs for ovarian cancer

AU - Lorusso, Domenica

AU - Pietragalla, Antonella

AU - Mainenti, Sara

AU - Di Legge, Alessia

AU - Amadio, Giulia

AU - Scambia, Giovanni

PY - 2010/12

Y1 - 2010/12

N2 - Importance of the field: Ovarian cancer has the highest mortality of all female reproductive tract cancers, which reflects both the absence of proven ovarian cancer screening tests and the development of drug-resistant cancer cell. Apart from varying the dosages, schedules, mode of delivery and combinations of existing drugs, efforts must continue to identify signaling pathways in tumor cells sufficiently different from normal cells that can be a target for maximizing tumor kill and minimizing toxicity. Areas covered in this review: Some of the most important cellular pathways are analyzed and discussed and the most interesting clinical trials, both closed and ongoing, described. What the reader will gain: The reader will gain a panoramic vision of all the most active drugs in clinical investigations in ovarian cancer. The reader will also better understand what the unresolved problems of molecular research are and how complicated the process 'from the bench to the bedside' is. Take home message: It is only with a strong commitment, cooperation and collaboration from the international ovarian cancer community that significant improvement in patient outcomes can be attained beyond the marginal gains achieved so far.

AB - Importance of the field: Ovarian cancer has the highest mortality of all female reproductive tract cancers, which reflects both the absence of proven ovarian cancer screening tests and the development of drug-resistant cancer cell. Apart from varying the dosages, schedules, mode of delivery and combinations of existing drugs, efforts must continue to identify signaling pathways in tumor cells sufficiently different from normal cells that can be a target for maximizing tumor kill and minimizing toxicity. Areas covered in this review: Some of the most important cellular pathways are analyzed and discussed and the most interesting clinical trials, both closed and ongoing, described. What the reader will gain: The reader will gain a panoramic vision of all the most active drugs in clinical investigations in ovarian cancer. The reader will also better understand what the unresolved problems of molecular research are and how complicated the process 'from the bench to the bedside' is. Take home message: It is only with a strong commitment, cooperation and collaboration from the international ovarian cancer community that significant improvement in patient outcomes can be attained beyond the marginal gains achieved so far.

KW - biological agents

KW - ovarian cancer

KW - target therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=78649482873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649482873&partnerID=8YFLogxK

U2 - 10.1517/14728214.2010.502888

DO - 10.1517/14728214.2010.502888

M3 - Article

VL - 15

SP - 635

EP - 652

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -